http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 07:00:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Successful Subscription to Raise £800,000 and PDMR Notifications</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 5, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html Thu, 05 Mar 2026 07:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Successful Subscription to Raise £800,000 and PDMR Notifications</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 5, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html Thu, 05 Mar 2026 07:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html <p><i><strong>Results of General Meeting</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.</p><p><strong>Proxy Voting Results</strong></p><table style="width:100%"><tbody><tr><td style="border:1.0pt solid windowtext;padding:0in 5.4pt;width:16.78%;"><p><strong>Ordinary Resolutions</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:16.34%;"><p><strong>Votes for</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:9.58%;"><p><strong>% of votes cast for</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:13.6%;"><p><strong>Votes Against</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:11.16%;"><p><strong>% of votes cast against</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html Mon, 02 Mar 2026 07:55:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html <p><i><strong>Results of General Meeting</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.</p><p><strong>Proxy Voting Results</strong></p><table style="width:100%"><tbody><tr><td style="border:1.0pt solid windowtext;padding:0in 5.4pt;width:16.78%;"><p><strong>Ordinary Resolutions</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:16.34%;"><p><strong>Votes for</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:9.58%;"><p><strong>% of votes cast for</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:13.6%;"><p><strong>Votes Against</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:11.16%;"><p><strong>% of votes cast against</strong></p></td><td style="border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html Mon, 02 Mar 2026 07:55:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html Mon, 02 Mar 2026 02:05:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html Mon, 02 Mar 2026 02:05:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / February 12, 2026 / </strong>Genflow Biosciences Plc http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html Thu, 12 Feb 2026 02:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / February 12, 2026 / </strong>Genflow Biosciences Plc http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html Thu, 12 Feb 2026 02:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Notice+of+GM/25977957.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Notice of General Meeting</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / February 11, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Notice+of+GM/25977957.html Wed, 11 Feb 2026 02:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Notice+of+GM/25977957.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Notice of General Meeting</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / February 11, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Notice+of+GM/25977957.html Wed, 11 Feb 2026 02:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Administrative+Approval+of+Grant+%26+2026+Priorities/25902548.html <p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / January 28, 2026 / </strong><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></p><p><strong>Genflow Biosciences Plc</strong></p><p><strong>Administrative Approval of €4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities</strong></p><p>Genflow Biosciences http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Administrative+Approval+of+Grant+%26+2026+Priorities/25902548.html Wed, 28 Jan 2026 02:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Administrative+Approval+of+Grant+%26+2026+Priorities/25902548.html <p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / January 28, 2026 / </strong><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></p><p><strong>Genflow Biosciences Plc</strong></p><p><strong>Administrative Approval of €4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities</strong></p><p>Genflow Biosciences http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Administrative+Approval+of+Grant+%26+2026+Priorities/25902548.html Wed, 28 Jan 2026 02:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion</strong></i></p><p><strong id="dateline">LONDON,UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / January 19, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html Mon, 19 Jan 2026 02:20:00 +0000 EDIT GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion</strong></i></p><p><strong id="dateline">LONDON,UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / January 19, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html Mon, 19 Jan 2026 02:20:00 +0000 EDIT GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion</strong></i></p><p><strong id="dateline">LONDON,UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / January 19, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html Mon, 19 Jan 2026 02:20:00 +0000 EDIT GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion</strong></i></p><p><strong id="dateline">LONDON,UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / January 19, 2026 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Directorate+Change/25861960.html Mon, 19 Jan 2026 02:20:00 +0000 EDIT GENFF http://www.streetinsider.com/Press+Releases/Genflow+Completes+Dosing+Phase+of+Canine+Gene+Therapy+Trial/25742459.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Completes Dosing Phase of Canine Gene Therapy Trial - No Adverse Events Reported During Administration</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / December 16, 2025 / </strong></p><p>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) http://www.streetinsider.com/Press+Releases/Genflow+Completes+Dosing+Phase+of+Canine+Gene+Therapy+Trial/25742459.html Tue, 16 Dec 2025 02:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Completes+Dosing+Phase+of+Canine+Gene+Therapy+Trial/25742459.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Completes Dosing Phase of Canine Gene Therapy Trial - No Adverse Events Reported During Administration</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / December 16, 2025 / </strong></p><p>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) http://www.streetinsider.com/ACCESS+Newswire/Genflow+Completes+Dosing+Phase+of+Canine+Gene+Therapy+Trial/25742459.html Tue, 16 Dec 2025 02:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+to+Attend+Healthcare+Conference/25725549.html <p><i><strong>Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / December 11, 2025 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12-15, 2026, at the Westin St. Francis in San Francisco, California.</p><p>J.P. Morgan's Healthcare Conference is the sector's most influential global investment gathering, connecting industry leaders, high-growth innovators, and the investment community. Genflow's participation provides an opportunity to engage with potential partners, institutional http://www.streetinsider.com/Press+Releases/Genflow+to+Attend+Healthcare+Conference/25725549.html Thu, 11 Dec 2025 02:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+to+Attend+Healthcare+Conference/25725549.html <p><i><strong>Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / December 11, 2025 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12-15, 2026, at the Westin St. Francis in San Francisco, California.</p><p>J.P. Morgan's Healthcare Conference is the sector's most influential global investment gathering, connecting industry leaders, high-growth innovators, and the investment community. Genflow's participation provides an opportunity to engage with potential partners, institutional http://www.streetinsider.com/ACCESS+Newswire/Genflow+to+Attend+Healthcare+Conference/25725549.html Thu, 11 Dec 2025 02:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/25532540.html <p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / October 31, 2025 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 31 October 2025 consists of 493,547,942 Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 493,547,942.</p><p>The figure of 493,547,942 Ordinary Shares may be used by shareholders of the Company as the http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/25532540.html Fri, 31 Oct 2025 03:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/25532540.html <p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / October 31, 2025 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 31 October 2025 consists of 493,547,942 Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 493,547,942.</p><p>The figure of 493,547,942 Ordinary Shares may be used by shareholders of the Company as the http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/25532540.html Fri, 31 Oct 2025 03:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Second+European+Patent+Application/25484174.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Publication of Second European Patent Application - SIRT6 Variant for NASH</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / October 22, 2025 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Second+European+Patent+Application/25484174.html Wed, 22 Oct 2025 02:00:00 +0000 GENFF http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Second+European+Patent+Application/25484174.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>Publication of Second European Patent Application - SIRT6 Variant for NASH</strong></i></p><p><strong id="dateline">LONDON, UK / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / October 22, 2025 / </strong>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Second+European+Patent+Application/25484174.html Wed, 22 Oct 2025 02:00:00 +0000 GENFF http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Recognition+of+Patentability+of+Claims/25472704.html <p><i><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></i></p><p><i><strong>Genflow Biosciences Plc</strong></i></p><p><i><strong>European Patent Office 2025 Recognizes the Patentability of Claims of SIRT 6 Variant Patent</strong></i></p><p><strong id="dateline">LONDON, UK, AL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / October 20, 2025 / </strong>Genflow Biosciences Plc http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Recognition+of+Patentability+of+Claims/25472704.html Mon, 20 Oct 2025 02:00:00 +0000 GENFF